Skip to main content

Table 3 Risk factors for overall survival, time to progress, and hepatic metastasis-free survival in the anti-HBc positive CRC patients undergoing curative surgical resection

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Variable

Overall survival

Time to progress

Hepatic metastasis-free survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

Anti-HBc

  ≥ 8.8

3.18

1.564–6.463

< 0.001*

3.51

1.718–7.17

< 0.001*

4.889

2.397–9.97

< 0.001*

5.747

2.789–11.842

< 0.001*

3.754

1.054–13.369

0.04*

3.754

1.054–13.369

0.04*

 < 8.8

Reference

                

FIB-4

                  

  ≥ 1.45

1.48

0.718–3.05

0.288

   

1.018

0.484–2.139

0.963

   

0.983

0.254–3.806

0.981

   

 < 1.45

Reference

                

NLR

                  

  ≥ 3.4

1.418

0.634–3.171

0.395

   

1.41

0.635–3.129

0.398

   

1.753

0.453–6.783

0.416

   

 < 3.4

Reference

                

Anti-HBs

 Positive

1.093

0.515–2.321

0.817

   

0.873

0.429–1.774

0.706

   

0.756

0.213–2.68

0.665

   

 Negative

Reference

                

HBsAg

 Positive

2.296

0.802–6.572

0.121

   

2.154

0.755–6.141

0.151

   

3.877

0.821–18.311

0.087

   

 Negative

Reference

                

Retrieved LN

  ≥ 12

0.983

0.453–2.135

0.966

   

0.94

0.447–1.975

0.869

   

1.66

0.352–7.82

0.521

   

 < 12

Reference

                

Neoadjuvant therapy

 Yes

0.735

0.175–3.083

0.674

   

1.544

0.542–4.395

0.416

   

0.043

0–729.474

0.527

   

 No

Reference

                

CEA (ng/ml)

                 

 > 5

1.286

0.636–2.602

0.484

   

0.911

0.453–1.831

0.793

   

3.352

0.867–12.965

0.08

   

  ≤ 5

Reference

                

CA19-9(U/ml)

                  

 > 37

1.683

0.725–3.907

0.226

   

1.282

0.529–3.106

0.582

   

0.634

0.08–5.008

0.666

   

  ≤ 37

Reference

                

TNM stage

                  

 III

2.731

1.285–5.802

0.01*

3.038

1.423–6.484

<0.001*

3.038

1.444–6.39

<0.001*

3.722

1.752–7.908

<0.001*

1.921

0.541–6.822

0.312

   

 II

Reference

                

Gender

                  

 Male

1.211

0.542–2.709

0.64

   

0.853

0.414–1.759

0.667

   

0.966

0.25–3.737

0.96

   

 Female

Reference

                

Age (years)

                  

  ≥ 61

1.124

0.554–2.28

0.747

   

0.922

0.466–1.825

0.816

   

0.896

0.259–3.094

0.862

   

 < 61

Reference

                
  1. Abbreviations: anti-HBc antibodies to hepatitis B core antigen, anti-HBs antibodies to hepatitis B surface antigen, HBsAg hepatitis B surface antigen, NLR neutrophil to lymphocyte ratio, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, PLT platelets
  2. *Significant at P < 0.05
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us